Emerging drugs for colorectal cancer

Expert Opinion on Emerging Drugs

Volumn 13, Issue 4, 2008, Pages 629-642

  Fogelman, David R ^a   Kopetz, Scott ^a   Eng, Cathy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bevacizumab; Cetuximab; Colorectal; Fluorouracil; Irinotecan; kRAS; mTOR; Oxaliplatin; VEGF

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ACNE; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DYSESTHESIA; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; MUCOSA INFLAMMATION; NAUSEA; NEPHROTIC SYNDROME; PARESTHESIA; PERIPHERAL NEUROPATHY; RASH; REVIEW; STOMATITIS; THROMBOSIS; VOMITING; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUGS, INVESTIGATIONAL; HUMANS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 58149240871     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210802544575     Document Type: Review

References (87)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96
2. Cancer Research UK. UK bowel statistics. Available from: http://info.cancerresearchuk. org/cancerstats/types/bowel
3. MacDonald J. Adjuvant therapy of colon cancer. CA Cancer J Clin 1999;49:202-19
4. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;2343-51
5. De Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years [abstract 4007]. J Clin Oncol Suppl 2007;25(Suppl 18S) •• This trial established oxaliplatin in the adjuvant setting.
6. Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14
7. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
8. Tournigand C, Andre T, Achille E, et al. Folfiri followed by Folfox6 or the reverse sequence in advanced colorectal cancer: a randomized Gercor study. J Clin Oncol 2004;22:229-37 • This study demonstrates equivalence in the choice of first chemotherapy.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42 •• This study, and [10], have established the role of bevacizumab and yet brought its effectiveness under scrutiny.
10. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J Clin Onc 2008;26:2013-9 •• Along with [9], this study established the role of bevacizumab while bringing its effectiveness under scrutiny.
11. Van Cutsem E, Nowacki M, Lang I, et al. Randomized Phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial [abstract #4000]. J Clin Oncol Suppl 2007;25(suppl 18S)
12. Adam R, Delwart V, Gerard P, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by Chemotherapy: A model to predict long-term survival. Ann Surg 2004;240:644-58
13. Pinedo HM, Peters G. Fluorouracil: Biochemistry and Pharmacology. J Clin Oncol 1988;6:1653-64
14. Petrelli N, Douglass HO, Herrera L, et al. The modulation of Fluorouracil with Leucovorin in Metastatic Colorectal Carcinoma A prospective randomized Phase III Trial. J Clin Oncol 1989;7:1419-26
15. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical Modulation of Fluorouracil: Evidence of significant improvement of survival and quality of life in patients with Advanced Colorectal Carcinoma. J Clin Oncol 7:1407-18
16. De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose Leucovorin and Fluorouracil Bolus with bimonthly high-dose leucovorin and Fluorouracil Bolus Plus continuous infusion for Advanced Colorectal Cancer: A French Intergroup Study. J Clin Oncol 1997;15:808-15
17. The Meta-Analysis Group in Cancer. Modulation of Fluorouracil by Leucovorin in patients with Advanced Colorectal Cancer: an Updated Meta-Analysis. J Clin Oncol 22:3766-75
18. The Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of Fluorouracil compared with Bolus administration in Advanced Colorectal Cancer J Clin Oncol16:301-8
19. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J Clin Oncol 2001;19:2282-92
20. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase III trials. Br J Cancer 2004;90:1190-7
21. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704
22. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of Fluoropyrimidines. J Clin Oncol 2008;26:2118-23
23. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909-13
24. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94
25. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8
26. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12
27. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic clorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7
28. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-86
29. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-71
30. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30 •• This was a pivotal study of oxaliplatin in combination with 5-FU.
31. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-75
32. Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-7
33. Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res 2006;12:4481-4
34. Nikcevich, ASCO 2008 oral presention. Abstract 4009
35. Grothey A, ASCO 2008 oral presentation
36. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a Phase III randomised controlled trial. Lancet 2007;370:135-42
37. Hochster HS, Hart L, Ramanathan RK, et al. Safety and efficacy of Oxaliplatin and Fluoropyrimidine Regimens with or without Bevacizumab as first-line treatment of Metastatic Colorectal Cancer: Results of the Tree Study. J Clin Oncol 2008;26:3523-9
38. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomized controlled trial. Lancet 2007;370:143-52
39. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14
40. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
41. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized Phase III Study of Capecitabine Plus Oxaliplatin compared with Fluorouracil/Folinic Acid Plus Oxaliplatin as first-line therapy for Metastatic Colorectal Cancer. J Clin Oncol 2008;26:2006-12
42. Purdie DM, Berlin JD, Flynn PJ, et al. The Safety of long-term bevacizumab use: results from the BriTE observational cohort study (OCS) [abstract 4103]. ASCO May 30 - June 3 2008, Chicago, Illinois
43. Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the U.S. (BRiTE) [abstract #3537]. ASCO 2006
44. Arnold D, Reinacher-Schick A, Muller L, et al; AIO, Colorectal Cancer Study Group, Bevacizumab beyond progression in combination with second-line chemotherapy (CT) after failure of a Bev containing first-line CT in patients (pts) with metastatic colorectal cancer (mCRC). Preliminary baseline and safety analysis from the AIO 0504/AGMT phase III study. ASCO 2008 Gastrointestinal Cancers Symposium Abstract #469. Available from: http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_ view&confID=53&abstractID=1068
45. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-18
46. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-2; discussion 80
47. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21:105-11
48. Bianchini D, Jayanth A, Chua YJ, et al. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Clin Colorectal Cancer 2008;7:33-4
49. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-34
50. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-204
51. Pippas AW, Lenz HJ, Mayer RJ, et al. Analysis of EGFR Status in Metastatic Colorectal Cancer Patients Treated with Cetuximab Monotherapy [abstract 3595]. ASCO 2005. Available from: www.asco.org
52. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10
53. Tejpar S, Peeters M, Humblet Y, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) [abstract #4001]. ASCO annual meeting; J Clin Oncol 2008;26
54. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25:4557-61
55. Amgen discontinues Vectibix treatment in PACCE trial evaluating Vectibix as part of Triple Combination Regimen. Available from: http://www. medicalnewstoday.com/articles/66111.php
56. Van Cutsem E, Peeters M, Siena S, et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
57. Allegra CJ, Parr AL, Wold LE, et al. Investigation of the Prognostic and Predictive Value of Thymidylate Synthse, p53, and Ki-67 in patients with locally advanced Colon Cancer. J Clin Oncol 2002;20:1735-43
58. Jensen SA, Vainer B, Sorensen JB. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 2006;120:694-701
59. Kornmann M, Schwabe W, Sander S, et al. Thymidilate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression Levels: predictors for survival in Colorectal Cancer patients receiving adjuvant 5-Fluorouracil. Clin Cancer Res 2003;9:4116-24
60. Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase 4xpression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2001;20:1721-8
61. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19(23):4298-304
62. Deeken JF, Slack R, Marshall JL. Irinotecan and Uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, t hat is the question. Cancer 2008;113(7):1502-10
63. Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008;98:923-30
64. Gold PJ, Iriarte D, Arthur J, et al. Phase II trial of Rad001 in patients with refractory metastatic colorectal cancer, ASCO Gastrointestinal Cancers Symposium, 2008 [abstract #513]
65. Phase I/Randomized Phase II Study of Second Line Therapy with Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer; Study Chair Gabriela Chiorean, MD. Available from: www.ClinicalTrials.gov. Identifier numbers NCT00522665 and NCT00478634
66. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006;12(5):1398-401
67. Eng C, Kopetz S, Morris J, et al. Phase II study of the novel oral Src-kinase inhibitor, AZD0530 in previously treated advanced colorectal cancer patients [abstract LB-76]. AACR 2008 annual meeting
68. Lu Y, Li X, Liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody Cetuximab. Cancer Res 2007;67:8240-7
69. Kopetz S. Targeting SRC and epidermal growth factor receptor in Colorectal Cancer: rationale and progress into the clinic. Gastrointest Cancer Res 2007;1:S37-41
70. Griffiths GJ, Koh MY, Brunton VG, et al. Expression of kinase-defective mutants of C-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem 2004;279:46113-21
71. Kopetz S, Shah AN, Gallick GE. SRC continues aging: current and future clinical directions. Clin Cancer Res 2007;13:7232-6
72. Kopetz S, Wolff RA, Eng CE, et al. Phase IB study of Src inhibition with dasatinib in combination with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metasatic colorectal cancer, Proceedings of the 98th Annual Meeting of the American Association for Cancer Research. San Diego, A AACR 2008, #LB-69
73. Calcagno SR, Li S, Colon M, et al. Oncogenic Kras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer 2008;122:2462-70
74. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic Kras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40:600-8
75. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5
76. Van Cutsem E, Lang I, D'Haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximan: the CRYSTAL experience [abstract #2]. ASCO 2008; Available from: www.asco.org
77. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Ibid. J Clin Oncol 2008;26(10):1626-34
78. Khambata-Ford S, Garrett CR, et al. Expression of epiregulin and amphiregulin and Kras mutation status predict disease control in metastatic colorectal cancer patients. J Clin Oncol 2007;25(22):3230-7
79. Loupakis F, Pollina L, Stasi I, et al. Evaluation of PTEN expression in colorectal cancer (crc) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment [abstract 4003]. J Clin Oncol 2008;26(May 20 suppl)
80. Wang Y, Van Becelaere K, Jiang P, et al. A role for Kras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 2005;7:336-47
81. Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007;67:4933-9
82. Available from: www.clinicaltrials.gov
83. Lang I, Adenis A, Boer K, et al. AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy [abstract 4114]. J Clin Oncol 2008;26:(May 20 suppl)
84. Garrett CR, Siu LL, El-Khoueiry AB, et al. A Phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy
85. Abhyankar V, Sharma S, Trowbridge RC, et al. Axitinib (AG-013736) in combination with Folfox and bevacizumab (Bev) in patients (pts) with metastatic solid tumors: A Phase I study [abstract 4112]. J Clin Oncol 2008;26:(May 20 suppl)
86. Yamada Y, Goto A, Ura T, Prognostic and predictive significance of insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), and HER2 in metastatic colorectal cancer[abstract #9649]. ASCO 2005
87. Tournigand C, Cervantes A, Figer A, et al. Optimox1: a Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in a Stop-and-Go fashion in advanced Colorectal Cancer - A GERCOR Study. J Clin Oncol 2006;24:394-400